Apigenin

Apigenin at a Glance

Apigenin is a dietary flavone found in chamomile, parsley and celery — the flavone sibling of luteolin, differing by a single hydroxyl on the B-ring.

Its reputation is the “chamomile before bed” one, and the mechanism proposed for it is specific: apigenin binds the benzodiazepine site of the GABA-A receptor, the same site diazepam acts on, though far more weakly. That is a genuinely interesting mechanism for a food compound.

The human evidence belongs to chamomile rather than to apigenin. The anxiety and sleep trials used whole chamomile extract, with apigenin the presumed active — no trial of the isolated molecule exists. That distinction is the central thing to carry into everything below.

What It's Used For

Apigenin is a dietary flavone — the flavone sibling of luteolin (apigenin plus a B-ring 3′-hydroxyl is luteolin) and the 3-deoxy analogue of the flavonol kaempferol. Its popular reputation, the “chamomile before bed” calm, rests on an inference rather than a trial: there is no randomized controlled trial of isolated apigenin for any human outcome. The anxiety and sleep evidence comes from whole chamomile extract (standardized to ~1.2% apigenin), and apigenin is only the presumed active because it binds the GABA-A benzodiazepine site in vitro — a mechanism that turns out to be genuinely mixed ^{13,14Reference 13Viola H et al. · 1995Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine-receptor ligand with anxiolytic effectsView study →Reference 14Avallone R et al. · 2000Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla (benzodiazepine-site binding but reduced Cl⁻ current and no anxiolysis alone)View study →}.

Everything else (anticancer, anti-inflammatory, metabolic) is cell-culture and animal work, undercut further by apigenin’s poor bioavailability: oral doses reach only low-nanomolar plasma levels, ~100–1000× below the concentrations used in those studies ^{17,18Reference 17Meyer H et al. · 2006Bioavailability of apigenin from apiin-rich parsley in humansView study →Reference 18Borges G et al. · 2022Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adultsView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume, tempered for isolate-vs-plant match and bioavailability. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. For apigenin every score is capped low — there is no isolate trial, so even the best “human” evidence is a whole-chamomile study or a dietary-intake association. Each application links to its write-up.

01Anxiety (as chamomile extract)Shaky35%Whole-chamomile RCTs in GAD; not isolated apigenin; single dominant research group ^{1,2Reference 1Amsterdam JD et al. · 2009RCTA randomised, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalised anxiety disorderView study →Reference 2Mao JJ et al. · 2016RCTLong-term chamomile (Matricaria chamomilla L.) treatment for generalised anxiety disorder — a randomised clinical trialView study →}

02Sleep quality (as chamomile extract)Shaky25%Whole-chamomile RCTs; mixed — negative in insomnia, positive in the elderly ^{4,5,6Reference 4Zick SM et al. · 2011RCTPreliminary examination of the efficacy and safety of a standardised chamomile extract for chronic primary insomnia — a randomised placebo-controlled pilot studyView study →Reference 5Adib-Hajbaghery M · 2017Clinical trialThe effects of chamomile extract on sleep quality among elderly people — a clinical trialView study →Reference 6Hieu TH et al. · 2019Meta-analysisTherapeutic efficacy and safety of chamomile for state anxiety, generalised anxiety disorder, insomnia, and sleep quality — a systematic review and meta-analysisView study →}

03Anticancer, anti-inflammatory & metabolicShaky15%Preclinical mechanism + dietary-flavone epidemiology; no human isolate data ^{7,9,11Reference 7Gates MA et al. · 2007A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancerView study →Reference 9Shukla S · 2010Apigenin — a promising molecule for cancer preventionView study →Reference 11Zhang X et al. · 2014Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophagesView study →}

Mechanisms

The GABA-A story deserves a flag: some rodent work shows anxiolysis without sedation, other work reports inverse-agonist/proconvulsant effects and no anxiolysis, with both flumazenil-sensitive and -insensitive components ^{13,14,15Reference 13Viola H et al. · 1995Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine-receptor ligand with anxiolytic effectsView study →Reference 14Avallone R et al. · 2000Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla (benzodiazepine-site binding but reduced Cl⁻ current and no anxiolysis alone)View study →Reference 15Campbell EL et al. · 2004The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA-A receptorsView study →}. The mechanism is real but not clean — and, like the others, mostly demonstrated at micromolar concentrations the bloodstream doesn’t reach.

Pharmacokinetics

Apigenin is a textbook “great in a dish, disappointing in a body” flavone. The aglycone is highly lipophilic and nearly water-insoluble, and in plants it is stored as glycosides — apiin (apigenin-7-apiosylglucoside, the parsley/celery form) and apigenin-7-O-glucoside (the chamomile marker) — whose sugar sets where absorption happens: chamomile’s glucoside peaks earlier (upper-GI) than parsley’s apiosylglucoside, which waits for colonic bacteria ^{18Reference 18Borges G et al. · 2022Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adultsView study →}. In the cleanest human study, an apiin-rich parsley dose gave a mean peak plasma apigenin of only 127 nmol/L at ~7 h, with just ~0.2% of the dose recovered in urine and inter-individual variability roughly two-thirds of the mean ^{17Reference 17Meyer H et al. · 2006Bioavailability of apigenin from apiin-rich parsley in humansView study →}. What little is absorbed is heavily conjugated, so the circulating species are apigenin glucuronides and sulfates, not the free aglycone ^{18Reference 18Borges G et al. · 2022Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adultsView study →}.

This is the load-bearing caveat: most mechanistic studies use 5–100 µM applied to cells, while achievable human plasma sits in the low-to-mid nanomolar range — roughly 100–1000× lower, and mostly as inactive conjugates ^{17,19Reference 17Meyer H et al. · 2006Bioavailability of apigenin from apiin-rich parsley in humansView study →Reference 19DeRango-Adem EF · 2021Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers? Frontiers in Pharmacology, 12, 681477. https://pubmed.ncbi.nlm.nih.gov/34084146/View study →}. Much of the current formulation research (nanoparticles, phospholipid complexes) exists specifically to close that gap ^{19Reference 19DeRango-Adem EF · 2021Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers? Frontiers in Pharmacology, 12, 681477. https://pubmed.ncbi.nlm.nih.gov/34084146/View study →}. The honest read: apigenin’s vivid in-vitro pharmacology is hypothesis-generating, not what a capsule delivers to tissue.

Clinical trials

Apigenin has no completed trial as an isolated molecule. Its human evidence is entirely trials of whole chamomile extract (anxiety, sleep) plus dietary-flavone epidemiology; the rest is preclinical.

Efficacy trials (isolate)	Whole-chamomile trials	Dietary epidemiology	Preclinical
None	Several (anxiety, sleep)	Cohorts (flavone intake)	Extensive

Last checked: July 2026.

Monoamine oxidase (MAO) inhibition

Apigenin is also reported as an in-vitro monoamine-oxidase inhibitor (with sub-micromolar MAO-A potency in some isolated-enzyme assays), one of several flavonoid MAO inhibitors ^{16Reference 16Salehi B et al. · 2019The therapeutic potential of apigeninView study →}. As with the others the activity is modest next to the β-carbolines and, given apigenin’s very low systemic and brain exposure, is best read as an in-vitro property rather than a clinical effect. See the natural MAO inhibitors guide for the comparison.

Isolate vs. Plant Studies

Apigenin is a case study in mistaking a herb for its molecule. The human evidence is chamomile, not apigenin: the anxiety and sleep RCTs test a standardized whole extract, and apigenin is the presumed active only by mechanistic inference ^{1,14Reference 1Amsterdam JD et al. · 2009RCTA randomised, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalised anxiety disorderView study →Reference 14Avallone R et al. · 2000Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla (benzodiazepine-site binding but reduced Cl⁻ current and no anxiolysis alone)View study →}. In plants it is a glycoside, not the aglycone (apiin, cosmosiin), which absorbs differently and is what a “apigenin-containing” herb actually delivers ^{18Reference 18Borges G et al. · 2022Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adultsView study →}. And several repo “apigenin” findings are really distinct C-glycosides — vitexin (apigenin-8-C-glucoside) and isovitexin (apigenin-6-C-glucoside) are separate molecules with their own pharmacology, and in one chickweed study the C-glycosides were inactive antioxidants while other flavones were active — so attributing that to “apigenin” would be wrong. Across the database apigenin is named in the flavonoid fraction of many herbs — chamomile, holy basil, passionflower, dandelion, hyssop — usually as a whole-extract contributor without an apigenin-specific assay. The single most apigenin-specific pharmacology finding actually complicates the sleep story: injected alone, isolated apigenin bound the benzodiazepine site but reduced GABA-A currents and produced no anxiolytic, myorelaxant or anticonvulsant effect ^{14Reference 14Avallone R et al. · 2000Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla (benzodiazepine-site binding but reduced Cl⁻ current and no anxiolysis alone)View study →}. Read the calm as a chamomile-extract effect, not a demonstrated property of the molecule.

A newer attribution needs the same discipline applied in advance. Apigenin has been identified by UPLC-QTOF-MS/MS among 33 flavonoids in the methanolic fraction of Cestrum nocturnum (hasana) leaf, and singled out as the fraction’s principal active compound against hepatocellular carcinoma — but that designation came from ADMET filtering, Lipinski screening and network-pharmacology target prediction, mapping 92 predicted apigenin targets onto 627 disease genes and 13 enriched pathways (oestrogen, VEGF, PI3K/AKT1, TNF, FoxO, Ras) ^{27Reference 27Kumar P et al. · 2022Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of Cestrum nocturnum L. to uncover mechanism of action on hepatocellular carcinoma — in silico network-pharmacology predictionView study →}. No cell, animal or human experiment was performed on the compound. It is a computational hypothesis about which molecule in a mixture is worth testing, and should be read as an in-silico prediction rather than an anticancer finding.

Prevalence in Nature

Apigenin is one of the most widely distributed dietary flavones, across the Apiaceae (parsley, celery, celery seed), Asteraceae (chamomile) and Lamiaceae (thyme, oregano), plus scattered fruits and leafy vegetables ^{26Reference 26U.S et al. · 2013U.S. Department of Agriculture, Agricultural Research Service. USDA Database for the Flavonoid Content of Selected Foods, Release 3.1 (2013) — apigenin, mg/100 g. https://www.ars.usda.gov/ARSUserFiles/80400525/Data/Flav/Flav3-1.pdfView study →}. It also occurs in the Solanaceae: the leaf of Cestrum nocturnum (hasana) carries it among a 33-flavonoid profile ^{27Reference 27Kumar P et al. · 2022Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of Cestrum nocturnum L. to uncover mechanism of action on hepatocellular carcinoma — in silico network-pharmacology predictionView study →}. It is almost never present as the free aglycone — it accumulates as glycosides: apiin (apigenin-7-O-apiosylglucoside) in parsley and celery, apigenin-7-O-glucoside (cosmosiin, the chamomile marker), and C-glycosides such as vitexin and isovitexin. Food databases report aglycone-equivalents after hydrolysis, so a listed “apigenin” figure sums free plus bound forms.

The dominant quantitative caveat is drying. Dried parsley (~4,504 mg/100 g) dwarfs every other food — roughly 20× fresh parsley and ~230× fresh celery — but that is a desiccation artifact (drying concentrates, it doesn’t create the compound), so it is held here in prose rather than on the chart. Fresh parsley (~216 mg/100 g) is still by far the richest common fresh source, with celery seed, vine (Malabar) spinach, chamomile flowers, Chinese celery, kumquat and celery hearts forming the tiers below it ^{25,26Reference 25Xie XY et al. · 2014Simultaneous determination of eight flavonoids in the flowers of Matricaria chamomilla by HPLC (apigenin 0.54–0.62 mg/g dried flower)View study →Reference 26U.S et al. · 2013U.S. Department of Agriculture, Agricultural Research Service. USDA Database for the Flavonoid Content of Selected Foods, Release 3.1 (2013) — apigenin, mg/100 g. https://www.ars.usda.gov/ARSUserFiles/80400525/Data/Flav/Flav3-1.pdfView study →}. Chamomile tea and dried oregano/thyme deliver only modest amounts.

Biosynthetically apigenin is a core flavone: naringenin is oxidized to apigenin by flavone synthase — the soluble FNS I (a dioxygenase, characteristic of Apiaceae like parsley) or the membrane P450 FNS II ^{24Reference 24Martens S · 2005Flavones and flavone synthasesView study →}. It carries no B-ring 3′-hydroxyl, so flavonoid 3′-hydroxylase acting on apigenin gives luteolin — apigenin is luteolin’s des-3′-OH sibling, and the flavone analogue of the flavonol kaempferol (which differs only by a 3-OH). There is essentially no non-plant source: animals don’t make it, and gut microbiota deglycosylate and degrade it (they can even reduce luteolin to apigenin) rather than synthesize it, so diet is the only meaningful source.

Discovery & Synthesis

The name comes straight from the plant: apigenin is derived from Apium, the botanical genus of celery and parsley (Apiaceae), reflecting its abundance there. The lineage runs through its glycoside — apiin (the apigenin-apiosylglucoside) was among the earliest flavonoid glycosides described, reported in 1843 from parsley/celery, with the branched sugar apiose characterized later. A single, confidently attributed “first isolation of the free apigenin aglycone” is not reliably documented, so it should not be asserted — what is safe to say is that the name honors Apium and the parent glycoside apiin was isolated from parsley/celery in 1843.

Structurally apigenin is 4′,5,7-trihydroxyflavone — a flavone (2-phenylchromen-4-one) hydroxylated at 5, 7 and 4′. Add a 3′-OH and it becomes luteolin; add a 3-OH (on the C-ring) and you have the flavonol kaempferol — apigenin sits at the center of that little family. Commercially it is obtained by extraction and purification from plant material (parsley, celery/celery seed, and especially chamomile flowers), typically by hydrolyzing the natural glycosides to liberate the aglycone; although apigenin is readily made by classical flavone synthesis, total synthesis is not the commercial route.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Apigenin is a common dietary flavone — eaten daily in parsley, celery and chamomile — and at dietary levels has a long record of low toxicity. The honest limitation is that there is very little controlled human safety data on isolated, supplemental apigenin; safety at concentrated supplement doses (often 50–100+ mg, far above dietary intake) is inferred, not established, and its poor absorption is not a demonstrated guarantee.

The interaction signals are mostly in-vitro and, because achievable plasma is nanomolar, of uncertain clinical weight — but worth noting for concentrated supplements. Apigenin is a competitive inhibitor of CYP2C9 (IC50 ~4–8 µM, e.g. losartan/diclofenac probes) ^{20Reference 20Wang Z et al. · 2016In vitroInhibitory effect of apigenin on losartan metabolism and CYP2C9 activity in vitroView study →} and inhibits CYP3A4 ^{21Reference 21Kondža M et al. · 2021Characterisation of the CYP3A4 enzyme inhibition potential of selected flavonoidsView study →}, raising a theoretical concern for CYP2C9 substrates (warfarin, some NSAIDs) and CYP3A4 substrates — most plausibly at the gut wall. It modulates P-glycoprotein in vitro ^{22Reference 22Bai J et al. · 2019In vitroInhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo — food/herb–drug interactions and structure–activity relationshipsView study →}. It is a weak phytoestrogen, acting as a partial estrogen-receptor agonist in vivo (with some ERβ preference), a basis for caution in hormone-sensitive conditions ^{23Reference 23Yao L et al. · 2021AnimalApigenin acts as a partial agonist action at estrogen receptors in vivoView study →}. And because it binds the GABA-A benzodiazepine site ^{13Reference 13Viola H et al. · 1995Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine-receptor ligand with anxiolytic effectsView study →}, there is a theoretical risk of additive CNS depression with benzodiazepines, alcohol or other sedatives — the one interaction most relevant to the “apigenin for sleep” use.

Dosage

There is no evidence-based dose of isolated apigenin, because no trial has tested it. The popular ~50 mg/day “sleep/longevity” regimen is extrapolated from chamomile-extract trials, cell/animal data and folklore — not from any human trial of the molecule. Where chamomile itself is dosed for anxiety it is a standardized extract (~1.2% apigenin, ~220–1500 mg/day of extract), which is a chamomile dose, not an apigenin dose ^{1,2Reference 1Amsterdam JD et al. · 2009RCTA randomised, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalised anxiety disorderView study →Reference 2Mao JJ et al. · 2016RCTLong-term chamomile (Matricaria chamomilla L.) treatment for generalised anxiety disorder — a randomised clinical trialView study →}.

These are descriptive, not a recommendation — no dose of isolated apigenin has been shown to do anything in a human trial. Anyone considering a supplement should note the sedative, CYP and estrogenic signals above and seek professional guidance.

References

1. Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. (2009). A randomised, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalised anxiety disorder. Journal of Clinical Psychopharmacology, 29(4), 378–382. https://pubmed.ncbi.nlm.nih.gov/19593179/
2. Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. (2016). Long-term chamomile (Matricaria chamomilla L.) treatment for generalised anxiety disorder — a randomised clinical trial. Phytomedicine, 23(14), 1735–1742. https://pubmed.ncbi.nlm.nih.gov/27912875/
3. Keefe JR, Guo W, Li QS, Amsterdam JD, Mao JJ. (2018). An exploratory study of salivary cortisol changes during chamomile extract therapy of moderate to severe generalised anxiety disorder. Journal of Psychiatric Research, 96, 189–195. https://pubmed.ncbi.nlm.nih.gov/29080520/
4. Zick SM, Wright BD, Sen A, Arnedt JT. (2011). Preliminary examination of the efficacy and safety of a standardised chamomile extract for chronic primary insomnia — a randomised placebo-controlled pilot study. BMC Complementary and Alternative Medicine, 11, 78. https://pubmed.ncbi.nlm.nih.gov/21939549/
5. Adib-Hajbaghery M, Mousavi SN. (2017). The effects of chamomile extract on sleep quality among elderly people — a clinical trial. Complementary Therapies in Medicine, 35, 109–114. https://pubmed.ncbi.nlm.nih.gov/29154054/
6. Hieu TH, Dibas M, Surya Dila KA, et al. (2019). Therapeutic efficacy and safety of chamomile for state anxiety, generalised anxiety disorder, insomnia, and sleep quality — a systematic review and meta-analysis. Phytotherapy Research, 33(6), 1604–1615. https://pubmed.ncbi.nlm.nih.gov/31006899/
7. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. (2007). A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. International Journal of Cancer, 121(10), 2225–2232. https://pubmed.ncbi.nlm.nih.gov/17471564/
8. Chang H, Lei L, Zhou Y, Ye F, Zhao G. (2018). Dietary flavonoids and the risk of colorectal cancer — an updated meta-analysis of epidemiological studies. Nutrients, 10(7), 950. https://pubmed.ncbi.nlm.nih.gov/30041489/
9. Shukla S, Gupta S. (2010). Apigenin — a promising molecule for cancer prevention. Pharmaceutical Research, 27(6), 962–978. https://pubmed.ncbi.nlm.nih.gov/20306120/
10. Rahmani AH, Alsahli MA, Almatroudi A, et al. (2022). The potential role of apigenin in cancer prevention and treatment. Molecules, 27(18), 6051. https://pubmed.ncbi.nlm.nih.gov/36144783/
11. Zhang X, Wang G, Gurley EC, Zhou H. (2014). Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PLoS ONE, 9(9), e107072. https://pubmed.ncbi.nlm.nih.gov/25192391/
12. Shukla S, Kanwal R, Shankar E, et al. (2015). Apigenin blocks IKKα activation and suppresses prostate cancer progression (NF-κB suppression in TRAMP mice). PLoS ONE / Oncotarget. https://pubmed.ncbi.nlm.nih.gov/26379052/
13. Viola H, Wasowski C, Levi de Stein M, et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine-receptor ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. https://pubmed.ncbi.nlm.nih.gov/7617761/
14. Avallone R, Zanoli P, Puia G, Kleinschnitz M, Schreier P, Baraldi M. (2000). Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla (benzodiazepine-site binding but reduced Cl⁻ current and no anxiolysis alone). Biochemical Pharmacology, 59(11), 1387–1394. https://pubmed.ncbi.nlm.nih.gov/10751547/
15. Campbell EL, Chebib M, Johnston GA. (2004). The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA-A receptors. Biochemical Pharmacology, 68(8), 1631–1638. https://pubmed.ncbi.nlm.nih.gov/15451406/
16. Salehi B, Venditti A, Sharifi-Rad M, et al. (2019). The therapeutic potential of apigenin. International Journal of Molecular Sciences, 20(6), 1305. https://pubmed.ncbi.nlm.nih.gov/30875872/
17. Meyer H, Bolarinwa A, Wolfram G, Linseisen J. (2006). Bioavailability of apigenin from apiin-rich parsley in humans. Annals of Nutrition & Metabolism, 50(3), 167–172. https://pubmed.ncbi.nlm.nih.gov/16407641/
18. Borges G, Fong RY, Ensunsa JL, et al. (2022). Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radical Biology & Medicine, 185, 90–96. https://pubmed.ncbi.nlm.nih.gov/35452808/
19. DeRango-Adem EF, Blay J. (2021). Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers? Frontiers in Pharmacology, 12, 681477. https://pubmed.ncbi.nlm.nih.gov/34084146/
20. Wang Z, Gong Y, Zeng DL, et al. (2016). Inhibitory effect of apigenin on losartan metabolism and CYP2C9 activity in vitro. Pharmacology, 98(1–2), 42–48. https://pubmed.ncbi.nlm.nih.gov/27287328/
21. Kondža M, Bojić M, Tomić I, Maleš Ž, Rezić V, Ćavar I. (2021). Characterisation of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules, 26(10), 3018. https://pubmed.ncbi.nlm.nih.gov/34069400/
22. Bai J, Zhao S, Fan X, et al. (2019). Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo — food/herb–drug interactions and structure–activity relationships. Toxicology and Applied Pharmacology, 369, 49–59. https://pubmed.ncbi.nlm.nih.gov/30790579/
23. Yao L, Fan Z, Han S, et al. (2021). Apigenin acts as a partial agonist action at estrogen receptors in vivo. European Journal of Pharmacology, 906, 174175. https://pubmed.ncbi.nlm.nih.gov/34048736/
24. Martens S, Mithöfer A (2005). Flavones and flavone synthases. Phytochemistry, 66(20), 2399–2407. https://pubmed.ncbi.nlm.nih.gov/16137727/
25. Xie XY, Chen FF, Shi YP. (2014). Simultaneous determination of eight flavonoids in the flowers of Matricaria chamomilla by HPLC (apigenin 0.54–0.62 mg/g dried flower). Journal of AOAC International, 97(3), 778–783. https://pubmed.ncbi.nlm.nih.gov/25051625/
26. U.S. Department of Agriculture, Agricultural Research Service. USDA Database for the Flavonoid Content of Selected Foods, Release 3.1 (2013) — apigenin, mg/100 g. https://www.ars.usda.gov/ARSUserFiles/80400525/Data/Flav/Flav3-1.pdf
27. Kumar P, Singh AK, Verma P, Tiwari KN, Mishra SK (2022). Network pharmacology-based study on apigenin present in the methanolic fraction of leaves extract of Cestrum nocturnum L. to uncover mechanism of action on hepatocellular carcinoma — in silico network-pharmacology prediction. Medical Oncology. https://pubmed.ncbi.nlm.nih.gov/35852639/

View all 27 references▾